Comparative Pharmacology
Head-to-head clinical analysis: MAVYRET versus VALCYTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAVYRET versus VALCYTE.
MAVYRET vs VALCYTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fixed-dose combination of glecaprevir (NS3/4A protease inhibitor) and pibrentasvir (NS5A inhibitor) that directly inhibits HCV viral replication by targeting viral proteins essential for polyprotein processing and RNA replication.
Valganciclovir is an L-valyl ester (prodrug) of ganciclovir. After oral administration, it is rapidly hydrolyzed to ganciclovir. Ganciclovir is phosphorylated to ganciclovir triphosphate, which inhibits viral DNA synthesis by competitive inhibition of viral DNA polymerase and incorporation into viral DNA, causing chain termination.
Three tablets (containing glecaprevir 100 mg and pibrentasvir 40 mg) taken orally once daily with food for 8 to 16 weeks depending on patient characteristics and prior treatment history.
For cytomegalovirus (CMV) retinitis in immunocompromised patients: 900 mg orally twice daily for 21 days, then 900 mg once daily as maintenance. For prevention of CMV in transplant recipients: 900 mg orally once daily starting within 10 days of transplant, continuing up to 100 days post-transplant.
None Documented
None Documented
Glecaprevir: 6 hours; pibrentasvir: 13 hours; supports once-daily dosing.
Terminal elimination half-life: 3-5 hours (valganciclovir) and 3.5-4.5 hours (ganciclovir, after conversion). In patients with renal impairment, half-life is prolonged: up to 10-30 hours depending on creatinine clearance. Hemodialysis reduces half-life to approximately 4-5 hours.
Primarily fecal (92%) with unchanged drug (50.3% glecaprevir, 63.8% pibrentasvir); renal elimination is minimal (<1%).
Renal excretion (primarily glomerular filtration and tubular secretion). Approximately 82-90% of the administered dose is recovered unchanged in urine. Fecal excretion is minimal (<5%). Biliary excretion is negligible.
Category C
Category C
Antiviral Agent
Antiviral Agent